Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
ELANCoalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind., Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has...
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
ELANNEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of...
Elanco Animal Health Reports Second Quarter 2025 Results
ELANRaising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growth Reported Net Income of $11 million, Adjusted Net Income of...
Elanco Animal Health Appoints Robert Vanhimbergen As Executive Vice President And Chief Financial Officer, Effective July 7, Vanhimbergen Succeeds Todd Young, Who Will Remain With The Company As An Advisor Through August 31
ELANWhat's Driving the Market Sentiment Around Elanco Animal Health?
ELANStifel Maintains Buy on Elanco Animal Health, Raises Price Target to $16
ELANStifel Maintains Buy on Elanco Animal Health, Raises Price Target to $15
ELANAnimal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
ELANElanco beat Q1 expectations with adjusted EPS of $0.37 and raised its 2025 revenue forecast, citing strong demand and favorable currency trends.
Is the Market Bullish or Bearish on Elanco Animal Health?
ELANElanco Animal Health Sees Q2 2025 Adj EPS $0.17-$0.21 vs $0.25 Est; Sees Sales $1.175B-$1.195B vs $1.17B Est
ELANElanco Animal Health Sees FY25 Adj EPS Of $0.80 - $0.86 Vs. $0.820 Est.
ELANElanco Animal Health Raises FY25 Revenue Guidance From $4.445B - $4.510B To $4.510B - $4.580B Vs. $4.484B Est.
ELANElanco Animal Health Q1 Adj. EPS $0.37 Beats $0.31 Estimate, Sales $1.19B Beat $1.17B Estimate
ELANElanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
ELANElanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.
Elanco Monetizes XDEMVY Royalties in $295M Deal to Lower Debt and Reduce Interest Costs
ELANLive On CNBC, Serat Sethi Announces Sold Elanco Animal Health; Bought Zoetis
ELANWhat Does the Market Think About Elanco Animal Health?
ELANStifel Maintains Buy on Elanco Animal Health, Lowers Price Target to $13
ELANPeering Into Elanco Animal Health's Recent Short Interest
ELANElanco Signs Research Agreement With WEDterinary To Explore Novel Therapies For Chronic Kidney Disease And Life Extension In Pets
ELANPiper Sandler Maintains Neutral on Elanco Animal Health, Lowers Price Target to $12
ELANUBS Maintains Buy on Elanco Animal Health, Lowers Price Target to $17
ELANMorgan Stanley Maintains Equal-Weight on Elanco Animal Health, Lowers Price Target to $13
ELANStifel Maintains Buy on Elanco Animal Health, Lowers Price Target to $15
ELANBarclays Maintains Overweight on Elanco Animal Health, Lowers Price Target to $19
ELANElanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff
ELANElanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.
Elanco Inks Agreement With South Dakota-Based Medgene To Commercialize Highly Pathogenic Avian Influenza Vaccine In Dairy Cattle
ELANElanco Animal Health Expects Q1 2025 Revenues Of $1.155B-$1.18B Versus Consensus Of $1.211B, With Adjusted EPS Of $0.29-$0.34 Versus Consensus Of $0.30
ELANElanco Animal Health Expects 2025 Revenues Of $4.445B-$4.51B Versus Consensus Of $4.533B, With Adjusted EPS Of $0.80-$0.86 Versus Consensus Of $0.90
ELANBeyond The Numbers: 5 Analysts Discuss Elanco Animal Health Stock
ELANStifel Maintains Buy on Elanco Animal Health, Lowers Price Target to $16
ELANElanco Acquires Speke Manufacturing Facility For $25M, Securing Critical Supply Chain For Farm Animal Products Generating $160M-$180M Annually; Expected To Impact 2025 Adjusted EBITDA By $25M-$35M
ELANElanco Animal Health Option Alert: Oct 21 $16 Calls Sweep (51) near the Ask: 1000 @ $0.75 vs 5916 OI; Earnings 11/4 Before Open [est] Ref=$15.275
ELANElanco Animal Health Option Alert: Nov 18 $17 Calls at the Ask: 3750 @ $0.95 vs 155 OI; Earnings 11/4 Before Open [est] Ref=$15.535
ELANWhat 7 Analyst Ratings Have To Say About Elanco Animal Health
ELANOver the past 3 months, 7 analysts have published their opinion on Elanco Animal Health (NYSE:ELAN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Barclays Maintains Equal-Weight on Elanco Animal Health, Lowers Price Target to $18
ELANHow To Attend Elanco Animal Health Q1 2022 Earnings Conference Call
ELANElanco Animal Health (NYSE:ELAN) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
How to Attend Elanco Animal Health (ELAN) Conference Call
Follow this link to access the live webcast.
